healthcare

Edesa Biotech Inc

news

A company to lose close to 25% in 3 days on no news shows Gary is absolutely USELESS.

$EDSA Whatever the news is (that somehow got leaked and is responsible for this going up more than 100% in a week) once it is properly announced I will GTFO and never come back to this Indian scammer Pars POS stock.

but watching APVO today is not very comforting for when we release news.

$EDSA These shitheads aren’t sharing the good news.

I simply want to see Edesa Biotech management try to put out any positive news release during this year and then realize that their news release once again had the opposite effect in moving the share price down another 41%+ during that day.

40-50% crushed on good news and then no rallies at all.

rate

Patients with rapidly improving ARDS still had a 55% mortality rate, much higher than earlier reported.

but embarrassingly, the FDA isn&#39;t impressed with an 84% death reduction rate? WTF?

3) QUESTIONABLE TRIAL GROUP - High placebo mortality rate and wide variance of dosed patients (L4 - L6) make it impossible to know what patient exactly should receive the  drug in Emergency Use, hence why they would like to see another trial.

Lowers the body temperature almost immediately, almost at an disturbing rate.

Short Borrow Fee rate has increased from approx 6% to 8% !!!!

approval

Still don’t think it deserved an 8k when we can’t even get main asset trial approval prs for years.

but it scares the shite out of me that the FDA has not approved our trial in over a year.

but starting phase 3 sometime this year, eb05 in trials and asking for fda phase 3 approval in numerous USA sites, just announced a EB06 trial starting in Canada and eb07 coming soon this would have to be the most idiotic bio company in Canadian history.

$EDSA they have 2 products, both of which are not FDA approved.

It seems a wee bit like some kind of half broken pump which had been purchased from a  bargain basement or fire sale clearance kind of vendor or a PUMP which would be purchased from some gold caps toothed Tamil Sri Lankan, lol.

1) Phase 3 FDA approval is imminent as it makes no sense for them to acknowledge the need for this drug and not be more flexible with the trial protocol.

The only reason VERU did not get EUA approval was due to a weak safety profile.

And the pipeline chart on website is so misleading cuz our P3 protocol is even not yet approved by FDA

business-result

$EDSA 

EBO1 Stat Sig results

Reached Primary Endpoint 

Dropped 44%? WTF?

$EDSA disappointing management hasn’t come out defending the EB01 results.

$EDSA long time bulls like Mr. Bitcoins are leaving forever after these terrible EB01 allergic contact dermatitis results … it’s over sad to say … at least the company tried their best,

But, let me tell you why the Bulls have disappointed me - nobody seemed able to defend these top line results and the Bears for being stupid lucky.

$EDSA Results were not good and even more concerning was that the higher regarded 2% dose showed nothing.

There may be potential to improve the results further.

but they can pass on their illness to others and, as a result, you need to protect yourself from them.

The delay is merely serving long ago determined intents on the part of this fack named Par and his fellow Edesa Biotech accomplices; and we may be losing just shy of every single penny we place here with Edesa Biotech Inc as a result.

executive

Edessa is dead and her CEO is a swindler.

Wouldn’t it be great if the CEO could even spare 1 hour every quarter to write a shareholder letter…

The CEO adding provides me no solace anymore.

Small buys by the President and CFO, and yet the share price just keeps collapsing.

$EDSA 

So these Healthcare workers were tested after the third booster, many young male and females who had a prior covid infection, suffered bad adverse reactions to the  boosters! Yay!

But what makes it amazing is the investor deck and website will still say  “in talks with fda on phase 3 approval”.

$EDSA Ruxolitinib (Opzelura) approved by FDA last year seems like a very solid drug for curing vitiligo and is generating tremendous revenue to Incyte.

FDA was pleased with their results and understands HC is moving forward.

* granted FDA fast track status late Dec 2022
* 75% of drugs given Fast Track get approved
* ARDS current has limited treatment options, could make a big impact 
* CEO has sold two previous biotech companies to bigger players 

Let’s get it 😍🎊💥🆙✅

Fast Tracked FDA status on a drug with no competition.

It looks like EB05 is gonna be that home run, with FDA ‘Fast Track’ designation at the end of Dec 2022, we’re almost at the finish line.

FDA mulling over Emergency use right now I bet 

Holding strong. .

but to PR the positive review and approval

They did exactly that with Fast Track, and also Compassionate Use

BOTH APPROVED BY FDA!

but my god everything has aligned for some very very very good news

$EDSA Not a single negative news about this stock and yet the price is falling .

$EDSA friends 
 
Great news 
 
In 2027 we might reach a profit 
 
Hahahahahahahahahaha

company

but I like what the company is trying to do/develop and the good it would do if successful.

$EDSA multiple billion dollar company. 🤦‍♀️

but this company never ceases to disappoint.

$EDSA Pretty pretty pretty neat  that myself and 3 other retail I know own around 5% of this company.

But, I do think good things are coming the way of this company before June.

$EDSA I’m literally so feed up with this company and stock.

One thing you have to give props to this company is their management of cash.

volume

$EDSA -9% on 50k volume is an astonishing accomplishment.

Short volume Ratio for last EIGHT straight trading days is averaging about 60%+

🧐

$EDSA last night&#39;s close was a very good close with very good share volume

however what we can see, apart from all our assumptions about it, right or wrong, the volumes are high compared to the previous months, which means a lot of interest in the title

$EDSA Reasonable volume everyday since 12/20.

$EDSA good volume today 1.5 of average 
We are on the right path

then news..then some real volume..up up and away

$EDSA the fact that this rise has been steady and medium volume is a good thing.

SELLAS Life Sciences Group Inc

buying

$SLS  I wont be buying anymore shares until the CEO can show is company is worth at least 150m marketcap 
 
Look at the 3 year chart be warned the CEO is a scam artist and a liar

You are better off hoarding cash vs buying into a company where the staff sells free shares and does not deserve pay raises during a economic crisis/recession.

$SLS  No one should be buying in at these prices though.

$SLS SERIOUSLY STOP FUCKING RUNNING ALL THE BUYING OTC DARK POOL!!!

This MM is refusing to honor order flow, they are refusing to move the price higher when buying comes in, they are dictating price direction and that&#39;s not their fucking job.

HOW THE FUCK DID THEY JUST FILL 24k BUYING VOLUME AND NOT A SINGLE $.01 MOVE!!!!

but buying inflow and a 5K buy order and yet POS MM will not let it fucking go!! !

application

Gfh009 is a joke and will ruin this stock until 3d meds sees fda approval for aml gps.

16/16 
In all 3 Options GPs gets FDA approval due to QOL, venclexta, onureg, oralAz - all Cr1 salvage agents are highly toxic.

This concerns me, we get the dreaded not statistically relevant ruling from the FDA.

- OUTRIGHT LIE saying THEN 52 weeks - PURE BS 
- OUTRIGHT LIE saying THEN patients need to Die 
Co is now on RECord Reiterating 80 Events, patient deaths in Q1Q2 
That is the fda green light moment.

announcement

You fucked up and shorted NCI non dilutive funding announcement and patients living longer news.

$SLS they supposedly hired a lawyer fill time and this was never announced .

The shorts feeling the pain on their announcement.

$SLS For those predicting some big announcement from Sellas on the 14th at the Regal symposium, you are going to be terribly disappointed.

investor

What a freaking smack in the face to investors.

Angelos has intentionally screwed the long term investor.

$SLS I find it arrogant that SLS would even investors were concerned about their SIVB exposure.

but after doing an offering and the way the market is, the company should be giving some communication,  otherwise you are showing you really don&#39;t care about long term  investors,  personally  I&#39;m not impressed with the way it&#39;s been handled.

$SLS This is a JOKE and the JOKE is on the real investors ☹️

$SLS SLS investors have two problems now.

If you’re an experienced investor and you buy this scam, you deserve to lose you your investment.

$SLS No one should buy  in to this unless you are new investor.

They need to communicate and support their investors and shareholders.

Scary that I bought 2 years ago 9000 shares $6.50 average price to see this today just seems like he doesn’t care at all for investors why would he?

A 300% gain in less than a month - and this time sis has plenty of cash in the tank to keep on running to the FDA green light.

$SLS my vote is get GPS green lighted for FDA approval and ramp this company up for M&amp;A.  GPS and GFH009 are high potential assets

Really is a great set up here - Get the FDA Green light and collect $50M plus another $25M warrants at $5.40.

$SLS In addition to GPs FDA approval for AML secondary Remission patients - Gps + Keytruda/Checkpoint Inhibition is also best in class for Ovarian cancer patients.

- Gps FDA Approval only a matter of time and is worth $8B in Market Value to Big Pharma  
- SlS current market cap of $.067B 
Best Short term investment any of us will find for a long. time.

Great Set Up here - $25M total incoming in Q1/2, Then another $50M when Gps gets the FDA green light - usually that is when small bios need to raise cash, and shorts can cover -- Ange Has them Over a barrel.

I think the share price will be climbing all along the approach to the FDA green light.

2,500% to 5,000% Upside in this ahead of the Fda Green light for Gps, as the first immunotherapy to treat 20,000 AML remission patients.

His 25-year experience, with global drug/biologics approvals and Breakthrough Therapy Designation with FDA, will be of immense value to our organization, especially as 2023 will be a pivotal year for our Company - welcome Andrew!

patient

It reported positive outcomes in pleural mesothelioma patients, including:
Improved survival: Study patients lived around 11 months.

* Best Available Therapy offers 6-8 months of Overall Survival  
* All pooled Regal patients, BAT and Gps combined, is 16 months.

* Best Available Therapy offers 6-8 months of Overall Survival 
* All pooled Regal patients, BAT and Gps combined, is 16 months.

Now phase 3 trial is showing similar results to date where patients are living longer after Galinpepimut-S up to 1.5 year longer is a breakthrough for AML patients.

- Best available treatment 6-8 months of os.

- Cured GPS patients, continue to elongate the OS curve in Gps favor every day that goes by.

$SLS NCT update, nice…
They target 140 patients in 110 investigational sites.

$SLS With news on its way, the confidence built in the science, fear factor is gone.

$SLS No breaking news here regarding Sellas, and its well above my understanding,

$SLS good news, at the current rate and the ridiculous prices, in about a month you can buy this company for free.

My guess is that they generated ~3m revenue through the EAP, which would be really great news.

This is a rare opportunity that you know the news is grossly good(it convinced in investor(s)) and still have the chance to load and make 50 to 100% in .month or so.

plenty of upside if there is positive news.

$SLS they picked a great day for this news. lol

So much for this offering being good news.

Positive trial data/results supported with bullish news and sentiment! 4.

trial

PROC data are excellent compared to any combo trials.

But yesterdays paper also has me considering, if there isn&#39;t a deal with $mrk or $BMY or some other CPI BP  
--- That data is Best In Class - best in clinic, best in trial too.

The nation’s best means the O&#39;Neal Comprehensive Center in Alabama have access to the latest therapies, cutting-edge clinical trials and the expertise needed to treat their cancer.

Gps is doing what it has done in every single trial and its the reason Patients are living 3 fold longer than patients on best available treatments.

Treatment with GFH009 resulted in 90 to 100 percent cancer inhibition at dose levels equivalent to those already demonstrated to be safe in patients in the ongoing Phase 1 trial with no viable cancer cells at the highest dose levels.

Mannkind Corp

vehicle

Needing more of the SAME ACTIVE ingredient means your delivery is less precise.

We don’t have enough electricity as is, and nobody has brought up the fact electric stoves are extremely inefficient transferring heat.

$MNKD the worst President in everyone’s lifetime, 🤡Joementia, at the beginning of his shitshow cancelled the Keystone XL pipeline requiring all that oil to be shipped in trucks and trains.

share

That is the reason MNKD share price has suffered lately.

$MNKD My biggest complaint is Management has been handed all these shares and really has no skin in the game.

All while leaving the share price of Mannkind at a pathetic 0.89 pre-split.

$MNKD SVB, the first thing that should happen is every single corporate officer that sold shares should be arrested minimally for fraud, handcuffed and placed in general population awaiting trial.

He may be so arrogant that he announce he&#39;s giving the board and himself a raise and free shares.

Still own my pre split shares and at a big paper loss!!!

It is problematic when every catalyst seems to have little effect on the company&#39;s share price and its perception in the market.

Last year, they paid only 50% of their dividend and that was $1.25 per share (absolutely insane).

The CEO has no backbone, thus the company has no backbone and, by consequence, the share price has no backbone.

but was horribly inefficient and required higher dosing to get mediocre Cmax.

Having a higher dose doesn’t mean anything when it doesn’t translate into improved efficacy and outcomes, which is the case here with Yutrepia’s inferior clinical trial outcomes and PK data.

$MNKD the administration and hierarchy of the mnkd corp could be a classic textbook case study at the college level for corporate greed, malfeasance, and management failure. .

$MNKD $LQDA 

Yutrepia Clinical Trial treatment related serious adverse events: 

Four patients experienced a severe treatment‐related AE during the trial.

price

$MNKD Look at the 6 &amp; 3 month charts, speaks for itself where this stock price is headed-DOWN!

The markets have performed horribly under Biden, and his policies have harmed the country and MNKD stock price.

That would definitely take UTHR stock price down.

When i set my order, automatically someone increase the price lol. .

$MNKD The problem with LQDA is that while this patent dispute goes on, it depresses UTHR stock price and along with it MNKD as DPI is put into question.

$MNKD this is sweetness here, hey how about sweetening our price a bit. ty

bear

$MNKD  
 
Never engage (including tagging) these professional trolls, that is how they make their bones.

$MNKD We are in a bear market in my opinion.

But with any significant developments at JPM Healthcare next week (positive commentary, guidance, surprise announcements, analyst coverage etc), this could go well above five dollars in a heartbeat, especially after such a long dryspell with no news.

MNKD and Al Mann deserve a whole lot of credit for the hardwork they put into getting a revolutionary Dry Powder Inhaled Delivery System, Manufacturing and a game changing insulin Afrezza FDA Approved.

With all the good things that have happened for MNKD, 2 FDA approvals and the deal with UTHR and this is where the stock price is.

Excellent scripts this  week amongst all 3 of our FDA approved products!

Explanation, Technosphere is a known and safe incipient as defined by the FDA and its use as such in drug delivery is now a known and accepted incipient!

It is now at $24 a share on news it received a favorable thumbs up from the FDA on a  phase 2 drug result.

We have 3 FDA approved drug revenue streams, lots of cash, &amp; a solid partnership with more coming.

Here at Mannkind we have…
-3 FDA approved drugs
-Revenue increasing quarter over quarter.

revenue

* Annual revenue grew 32% to  
   almost $100M vs 2021!

$MNKD I will continue to accumulate all the shares I can because of growing revenues, growing profits, and growing cash for many quarters and years to come.

* Afrezza annual net revenue 
   increased by double digits  
   every yr last 5 yrs to $43M+ 
* Afrezza Pediatric study  
   completion will upsurge sales  
    in this market!

$MNKD 

﻿Afrezza

First ten weeks of this year = $18.83 million 

First ten weeks of last year = $14.05 million

which represents 33.95% growth year-over-year

Plus, by then MNKD may have another large revenue stream and potentially others in the works.

$MNKD 
With the company being in the best position it ever has been as revenues continue to increase quarter over quarter it won’t take long before we are sitting at a new 52 week high! Cheers!🍸

Revenues are going to increase significantly.

$MNKD sustainable growing revenue streams…only a matter of time!

* UTHR has the highest rev &amp;  
    most profitable year ever  
    owing to Tyvaso DPI (T-DPI)!

They LOVE the CEO &amp; he can do no wrong. ..

$MNKD Long &amp; Strong as long as it takes.

market

That same pattern happened in October and the market had a decent run up.

The only thing I am confident about is its going to be much higher going into next year regardless of the market.

$MNKD holding up well in this bear market

$MNKD Well the markets are certainly impressed with the 950 Afrezza scripts. GO!!!

$MNKD Regardless of today or maybe even the next few months, MNKD has a lot of positives that should drive it higher when the market stops throwing out the baby with the bathwater.

Top Stocks matching your search for "healthcare fda"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

EDSA

Edesa Biotech Inc

-24.09%

$1.37 - $1.04

Feb, 26, 2023

SLS

SELLAS Life Sciences Group Inc

-63.99%

$3.61 - $1.30

Dec, 12, 2022

MNKD

Mannkind Corp

-21.71%

$5.25 - $4.11

Jan, 6, 2023

EDSA

Edesa Biotech Inc

-24.09%

$1.37 - $1.04

Feb, 26, 2023

SLS

SELLAS Life Sciences Group Inc

-63.99%

$3.61 - $1.30

Dec, 12, 2022

MNKD

Mannkind Corp

-21.71%

$5.25 - $4.11

Jan, 6, 2023